Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03931993 · ClinicalTrials.gov registry record · Phase 1
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
A Phase 1 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03931993 is a Phase 1 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT03931993, a Phase 1 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of subcutaneous (SC) injections or of sublingual administration. Previously, high cumulative doses of the Grass MATA MPL 10200 and 18200 SU (Standardized Units) were compared with the marketed dose of 5100 SU and were found to have acceptable tolerability and safety. The purpose of this study is to evaluate the tolerability and safety of an even higher cumulative dose regimen of 35600 SU. of Grass MATA MPL compared with placebo in patients with seasonal allergic rhinoconjunctivitis (SAR) due to grass pollen, to enable selection of the best dose to take forward for further development.
Interventions
- BIOLOGICAL Grass MATA MPL
- BIOLOGICAL Placebo comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-01-16 |
| Est. Completion | 2017-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03931993
The ClinicalTrials.gov registry entry for NCT03931993 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Grass MATA MPL is the first listed.
NCT03931993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03931993 about?
NCT03931993 is a clinical study titled "A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL". There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of subcutaneous (SC) injections or of sublingual administration. Previously, high cu...
What is the current status of trial NCT03931993?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-01-16. Estimated completion is 2017-04-27.
What interventions are being tested in trial NCT03931993?
The interventions under investigation include: Grass MATA MPL (BIOLOGICAL), Placebo comparator (BIOLOGICAL).
Who is sponsoring clinical trial NCT03931993?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.